Euroopan unioni - saksa - EMA (European Medicines Agency)

merck sharp & dohme b.v. - letermovir - cytomegalovirus-infektionen - antivirale mittel zur systemischen anwendung - prevymis ist indiziert zur prophylaxe von cytomegalovirus (cmv) reaktivierung und krankheit bei erwachsenen cmv-seropositiven empfänger [r +] eine allogene hämatopoetische stammzelltransplantation (hsct). es sollte erwogen werden, um die offiziellen richtlinien über die geeignete anwendung von virostatika.

Euroopan unioni - saksa - EMA (European Medicines Agency)

gedeon richter - cariprazinhydrochlorid - schizophrenie - psycholeptika - reagila ist indiziert zur behandlung von schizophrenie bei erwachsenen patienten.

Sveitsi - saksa - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - venetoclaxum - filmtabletten - venetoclaxum 10 mg, copovidonum k 28, polysorbatum 80, silica colloidalis anhydrica, calcii phosphas, natrii stearylis fumaras corresp. natrium 0.03 mg, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), pro compresso obducto. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika

Sveitsi - saksa - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - venetoclaxum - filmtabletten - venetoclaxum 50 mg, copovidonum k 28, polysorbatum 80, silica colloidalis anhydrica, calcii phosphas, natrii stearylis fumaras corresp. natrium 0.15 mg, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso obducto. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika

Sveitsi - saksa - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - venetoclaxum - filmtabletten - venetoclaxum 100 mg, copovidonum k 28, polysorbatum 80, silica colloidalis anhydrica, calcii phosphas, natrii stearylis fumaras corresp. natrium 0.31 mg, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), pro compresso obducto. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika

Sveitsi - saksa - Swissmedic (Swiss Agency for Therapeutic Products)

recordati ag - cariprazinum - hartkapseln - cariprazinum 1.5 mg ut cariprazini hydrochloridum, amylum pregelificatum, magnesii stearas, kapselhülle: gelatina, e 171, drucktinte: e 172 (nigrum), lacca, aqua purificata, propylenglycolum, kalii hydroxidum, pro capsula. - neuroleptikum - synthetika

Sveitsi - saksa - Swissmedic (Swiss Agency for Therapeutic Products)

recordati ag - cariprazinum - hartkapseln - cariprazinum 3 mg ut cariprazini hydrochloridum, amylum pregelificatum, magnesii stearas, kapselhülle: gelatina, e 129 0.3 µg, e 133, e 171, e 172 (flavum), drucktinte: e 172 (nigrum), lacca, aqua purificata, propylenglycolum, kalii hydroxidum, pro capsula. - neuroleptikum - synthetika

Sveitsi - saksa - Swissmedic (Swiss Agency for Therapeutic Products)

recordati ag - cariprazinum - hartkapseln - cariprazinum 4.5 mg ut cariprazini hydrochloridum, amylum pregelificatum, magnesii stearas, kapselhülle: gelatina, e 129 0.8 µg, e 133, e 171, e 172 (flavum), drucktinte: lacca, e 171, propylenglycolum, simeticonum, pro capsula. - neuroleptikum - synthetika

Sveitsi - saksa - Swissmedic (Swiss Agency for Therapeutic Products)

recordati ag - cariprazinum - hartkapseln - cariprazinum 6 mg ut cariprazini hydrochloridum, amylum pregelificatum, magnesii stearas, kapselhülle: gelatina, e 129 9.6 µg, e 133, e 171, drucktinte: e 172 (nigrum), lacca, aqua purificata, propylenglycolum, kalii hydroxidum, pro capsula. - neuroleptikum - synthetika

Euroopan unioni - saksa - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - karzinom, nicht kleinzellige lunge - antineoplastische mittel - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.